
Reviving Lilly’s Weight Loss Drug Sales: A Necessity for Investors in 2025 and Beyond
The Future of Eli Lilly’s Weight-loss Drug Zepatier: A Closer Look Recent developments in the pharmaceutical industry have left investors and analysts alike questioning the future growth prospects of Eli Lilly’s popular weight-loss drug, Zepatier. After the company reported lower-than-expected fourth-quarter revenues for the drug last month, there has been a growing demand for more…